XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

Gerardo Rosati(Ospedale San Carlo), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo), Alfredo Butera(Nuovo Ospedale San Giovanni di Dio), Giorgio Reggiardo(Data Management (Italy)), Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine)

Cancer Chemotherapy and Pharmacology

October 25, 2012

10.1007/s00280-012-2004-x

Cited by 23

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

|NEJM Evidence|2022|1.1k

Primary Tumor Response to Preoperative Chemoradiation With or Without Oxaliplatin in Locally Advanced Rectal Cancer: Pathologic Results of the STAR-01 Randomized Phase III Trial

|Journal of Clinical Oncology|2011|763

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer

|Journal of Clinical Oncology|2000|452